Consumption of drugs for Alzheimer's disease on the Brazilian private market.

IF 2.1 4区医学 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

Revista de saude publica Pub Date : 2023-11-10 eCollection Date: 2023-01-01 DOI:10.11606/s1518-8787.2023057005128

Evani Leite de Freitas, Sabrina Calil-Elias, Rafael Santos Erbisti, Branca Grinberg-Weller, Elaine Silva Miranda

{"title":"Consumption of drugs for Alzheimer's disease on the Brazilian private market.","authors":"Evani Leite de Freitas, Sabrina Calil-Elias, Rafael Santos Erbisti, Branca Grinberg-Weller, Elaine Silva Miranda","doi":"10.11606/s1518-8787.2023057005128","DOIUrl":null,"url":null,"abstract":"Objective: To analyze the consumption of drugs for Alzheimer's disease on the Brazilian private market and its geographical distribution from 2014 to 2020.Methods: National data from the Brazilian National System of Controlled Product Management were used, regarding sales of donepezil, galantamine, rivastigmine, and memantine from January 2014 to December 2020. Sales data were used as a proxy for drug consumption and expressed as defined daily dose/1,000 inhabitants/year at national, regional, federative unit and microregion levels.Results: Drug consumption went from 5,000 defined daily doses/1,000 inhabitants, in 2014, to more than 16,000/1,000 inhabitants, in 2020, and all federative units showed positive variation. The Brazilian Northeast had the highest cumulative consumption in the period but displayed microregional disparities while the North region had the lowest consumption. Donepezil and memantine were the most consumed drugs, with the highest growth in consumption from 2014 to 2020.Conclusion: The consumption of medicines indicated to treat Alzheimer's disease tripled in Brazil between 2014 and 2020, which may relate to the increase in the prevalence of the disease in the country, greater access to health services, and inappropriate use. This challenges managers and healthcare providers due to population aging and the increased prevalence of chronic-degenerative diseases.","PeriodicalId":21230,"journal":{"name":"Revista de saude publica","volume":"57 ","pages":"83"},"PeriodicalIF":2.1000,"publicationDate":"2023-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631752/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista de saude publica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.11606/s1518-8787.2023057005128","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To analyze the consumption of drugs for Alzheimer's disease on the Brazilian private market and its geographical distribution from 2014 to 2020.

Methods: National data from the Brazilian National System of Controlled Product Management were used, regarding sales of donepezil, galantamine, rivastigmine, and memantine from January 2014 to December 2020. Sales data were used as a proxy for drug consumption and expressed as defined daily dose/1,000 inhabitants/year at national, regional, federative unit and microregion levels.

Results: Drug consumption went from 5,000 defined daily doses/1,000 inhabitants, in 2014, to more than 16,000/1,000 inhabitants, in 2020, and all federative units showed positive variation. The Brazilian Northeast had the highest cumulative consumption in the period but displayed microregional disparities while the North region had the lowest consumption. Donepezil and memantine were the most consumed drugs, with the highest growth in consumption from 2014 to 2020.

Conclusion: The consumption of medicines indicated to treat Alzheimer's disease tripled in Brazil between 2014 and 2020, which may relate to the increase in the prevalence of the disease in the country, greater access to health services, and inappropriate use. This challenges managers and healthcare providers due to population aging and the increased prevalence of chronic-degenerative diseases.

查看原文本刊更多论文

巴西私人市场上治疗阿尔茨海默病的药物消费量。

目的:分析2014 - 2020年巴西阿尔茨海默病药物私人市场的消费情况及其地理分布。方法:使用巴西国家管制产品管理系统2014年1月至2020年12月的多奈哌齐、加兰他明、雷瓦斯汀和美金刚销售数据。使用销售数据作为药物消费的代表，并在国家、区域、联邦单位和微区域各级以定义日剂量/1,000居民/年表示。结果:药物消费量从2014年的5,000限定日剂量/1,000居民增加到2020年的16,000/1,000居民以上，所有联邦单位均呈阳性变化。巴西东北部在此期间的累计消费量最高，但存在微区域差异，而北部地区的消费量最低。2014 - 2020年，多奈哌齐和美金刚是消费量最大的药物，消费量增长最快。结论:2014年至2020年间，巴西用于治疗阿尔茨海默病的药物消费量增加了两倍，这可能与该国阿尔茨海默病患病率上升、卫生服务可及性增加以及使用不当有关。由于人口老龄化和慢性退行性疾病的患病率增加，这对管理人员和医疗保健提供者构成了挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista de saude publica PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-

CiteScore

4.60

自引率

3.60%

发文量

审稿时长

4-8 weeks

期刊介绍： The Revista de Saúde Pública has the purpose of publishing original scientific contributions on topics of relevance to public health in general.